Abstract:Background: Nasopharyngeal carcinoma (NPC), arising from nasopharynx epithelium, is a rare type of malignant carcinoma that has a specific geographical distribution and a high risk of distant metastases. For most of the diagnosed NPC patients, the total survival rate decreased significantly due to the high local recurrence rate and metastasis rate. Concurrent chemoradiotherapy (CCRT), as routine therapy strategy of NPC, usually accompanies with high-dosage cytotoxic agents and serious toxic side reaction. Therefore, there is an urgent need for update the existing therapy strategies. In this study, we sought to investigate the effects of a combined therapy strategy, erlotinib combined with cisplatin and radiotherapy, on biological characteristics of NPC CNE2 cells and the potential reasons. Methods: CNE2 cells in logarithmic phase seeding in 96-well plates received concentration gradients of erlotinib (at 0, 10, 20, 40, 80, 160, 320 mmol/L) or cisplatin (at 0, 0.25, 0.5, 1, 2, 4, 8 mg/L), in order to obtain the optimal working concentration of erlotinib and cisplatin via 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. Then, cells were divided into control group and four treatment groups (Group I-IV). All treatment groups received irradiation of 4 Gy, moreover, Group II-IV respectively received erlotinib, cisplatin and erlotinib plus cisplatin at optimal working concentration. After 24 and 48 h of irradiation, growth inhibition rate was determined; invasion ability and migration ability was respectively detected by Boyden's chamber assay and cell scratch test; flow cytometry was performed for determining apoptosis rate and cell cycle distribution; the expression levels of epidermal growth factor receptor (EGFR) signal pathway proteins were semi-quantitatively analyzed by Western-blot. Results: Compared with Group I, all the other treatment groups showed better inhibition effect on cell viability, invasion and migration ability and higher apoptosis rate, while Group IV showed the strongest growth inhibition effect and highest apoptosis rate. In addition, EGFR signal pathway proteins of Group IV showed the lowest expression level. Conclusions: In combined therapy with radiotherapy/chemotherapy, erlotinib could enhance radiotherapy/chemotherapy sensitivity, probably because it could suppress DNA damage repair after radiotherapy/chemotherapy, thus weakening radiotherapy/chemotherapy resistance of tumor cells.

Effect of Cetuximab Combined with Radiation on Nasopharyngeal Carcinoma Cell Lines

Identification of Prognostic Biomarkers for Response to Radiotherapy by DNA Microarray in Nasopharyngeal Carcinoma Patients

Cetuximab and Cisplatin Show Different Combination Effect in Nasopharyngeal Carcinoma Cells Lines via Inactivation of EGFR/AKT Signaling Pathway

Effectiveness of Cetuximab in Combination with Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A 1:2 Propensity Score-matched Analysis.

Clinical Study of Cetuximab Combined with Radiotherapy and Chemotherapy for Treating Advanced Nasopharyngeal Carcinoma

Cetuximab in Combination with Chemoradiotherapy in the Treatment of Recurrent And/or Metastatic Nasopharyngeal Carcinoma.

Erlotinib enhanced chemoradiotherapy sensitivity via inhibiting DNA damage repair in nasopharyngeal carcinoma CNE2 cells

Cetuximab in Combination with Chemoradiation after Induction Chemotherapy of Locoregionally Advanced Nasopharyngeal Carcinoma: Preliminary Results

The effects of cetuximab in combination with docetaxel for the acquired resistance to EGFR-TKI in non-small cell lung cancer cells

Radiosensitivity Enhancement by Combined Treatment of Nimotuzumab and Celecoxib on Nasopharyngeal Carcinoma Cells

Inhibitory Effect of Combination of Cetuximab and Irradiation on Colorectal Carcinoma CL187 Cells

Inhibition of N-acetylglucosaminyltransferase V Enhances the Cetuximab-Induced Radiosensitivity of Nasopharyngeal Carcinoma Cells Likely Through EGFR N-glycan Alterations

Clinical Outcomes and Prognostic Factors of Cetuximab plus Intensity-modulated Radiotherapy (IMRT)with Chemotherapy for Nasopharyngeal Carcinoma

combination treatment with cetuximab in advanced nasopharyngeal carcinoma patients: a meta-analysis

Long-Term Result of A Multicenter Clinical Study of Cetuximab Combined with Intensity Modulated Radiotherapy (imrt) Plus Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma (Npc).

Effect of P53 Knockdown on the Radiobiological Characteristics of Nasopharyngeal Carcinoma Cell Line CNE2

Intensity modulated radiation therapy combined with cetuximab and cisplatin in treatment of advanced nasopharyngeal carcinoma

Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study

Enhancing Nasopharyngeal Carcinoma Cell Radiosensitivity by Suppressing AKT/mTOR Via CENP-N Knockdown

An Open, Multicenter Clinical Study on Cetuximab Combined with Intensity Modulated Radiotherapy (imrt) Plus Concurrent Chemotherapy in Nasopharyngeal Carcinoma (npc): Preliminary Report

Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up